We at Mindpeak GmbH are very happy to announce the CE mark for our „Mindpeak Lung (NSCLC) PD-L1 (SP263) RoI“, a plug-and-play AI solution to detect and quantify PD-L1 expression within user-defined Regions of Interest (RoI) on non-small-cell lung cancer. In a study our software showed a 96.5% agreement for the most relevant scanners on the market. Mindpeak Lung PD-L1, our 7th CE marked product, is a milestone in supporting pathologists in the diagnosis of Lung Cancer, which is among the most difficult tasks for pathologists. It identifies tumorous cells and quantifies them to support TPS-scoring.
Mindpeak announces scanner agnostic CE-marked PD-L1 AI solution to support Lung Cancer Diagnosis
Related reading
%20(1).png)
Accelerating AI Adoption in Pathology: Mindpeak x PathGroup
The role of AI in pathology isn’t just evolving – it’s accelerating. It’s helping pathologists turn complex data into faster, more consistent answers for patients. At Mindpeak, we’re proud to be part of that change. Today, we’re taking another big step forward through a new collaboration with PathGroup – one of the leading providers of anatomic, clinical, molecular and digital pathology services in the U.S.
This partnership goes beyond collaboration; it marks a powerful step toward bringing AI into everyday diagnostics. By combining Mindpeak’s proprietary image analysis technology with PathGroup’s extensive, pathologist-led network, we’re laying the groundwork for a new era of precision and efficiency in pathology.
Together, we’ll support pathologists integrate AI seamlessly into their workflows – enhancing speed, consistency and equity in diagnostics. The result: faster, more reliable insights for patients and more time for pathologists to focus on what matters most – patient care.
At Mindpeak, we believe the future of pathology is AI-augmented, not AI-replaced. Through partnerships like this, that future is becoming reality – one slide at a time.
Read more here
PhenoScout AI: Advancing mIF Analysis
We’re proud to introduce PhenoScout AI, our next-generation multiplex immunofluorescence (mIF) analysis solution.
By automating phenotype identification, biomarker quantification, and spatial readouts, PhenoScout AI reduces variability and supports large-scale studies. The solution is designed for pharma, diagnostics, and academic research to accelerate translational medicine.
Mindpeak Welcomes Christiaan Neeleman to the Board of Directors
We are delighted to announce that Christiaan Neeleman has joined Mindpeak’s Board of Directors.
With more than 20 years of international leadership experience in life sciences, diagnostics, and health technology - including senior roles at Discovery Life Sciences, Definiens, and Philips Healthcare - Christiaan brings deep expertise that will help accelerate our global expansion.
His proven track record in biomarker development, companion diagnostics, and scaling precision diagnostics businesses aligns perfectly with Mindpeak’s mission: enabling faster, more accurate cancer diagnostics through AI-powered pathology.
We are excited to collaborate with Christiaan as we strengthen partnerships, expand into new markets, and further drive the adoption of AI across clinical and research settings.
Read the full press release here
Ready to advance your diagnostics
Connect with our team to explore how precision pathology works in your setting